Altogether, these results show that YTHDF2 downregulation enhances the anti‐tumour effect of cisplatin via both proliferation inhibition and sensitisation of ICC cells to cisplatin treatment (Figure 7L). Here, YTHDF2 is linked to intrahepatic cholangiocarcinoma.